MEDICUS PHARMA ANNOUNCES KOL ENDORSEMENT OF SKINJECT PHASE 2 RESULTS SHOWING 80% OVERALL RESPONSE RATE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy MDCX?
Source: moomoo
- Study Overview: Medius Pharma has reported on the validation of Phase 2 data for a skin injection treatment.
- Response Rate: The study indicates an overall response rate of 80% among participants.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDCX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDCX
Wall Street analysts forecast MDCX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.339
Low
12.00
Averages
12.00
High
12.00
Current: 0.339
Low
12.00
Averages
12.00
High
12.00
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medicus Pharma Submits Orphan Drug Designation for SkinJect®
- Orphan Drug Application: Medicus Pharma has submitted an Orphan Drug Designation application to the U.S. FDA for SkinJect® (D-MNA) targeting basal cell carcinoma in patients with Gorlin Syndrome, marking a strategic expansion into a high unmet need orphan indication that is expected to enhance market competitiveness.
- High-Burden Rare Disease: Gorlin Syndrome affects approximately 11,000 patients in the U.S., with individuals potentially developing dozens to over 1,000 basal cell carcinomas throughout their lives; current treatments rely heavily on surgery, lacking FDA-approved therapies, making SkinJect® a promising solution to alleviate both physical and psychological burdens on patients.
- Localized Treatment Advantages: SkinJect® is a dissolvable microneedle array designed for direct delivery of doxorubicin into tumor tissue, featuring high local concentration and minimal systemic exposure, which is particularly beneficial for managing multiple lesions in Gorlin Syndrome patients, potentially improving their treatment experience significantly.
- Clinical Research Progress: SkinJect® has demonstrated a favorable safety profile and evidence of clinical clearance in Phase 1 and Phase 2 studies for basal cell carcinoma; if granted orphan drug status, it will provide Medicus with 7 years of market exclusivity, enhancing its differentiated clinical and regulatory pathway.
See More
Medicus Pharma Files Application for Orphan Drug Designation with U.S. FDA for Skinject® in Gorlin Syndrome
- Medicus Pharma Submission: Medicus Pharma has submitted an application to the U.S. FDA for the designation of a new orphan drug.
- Targeted Condition: The application is specifically for the drug "Skinject®" aimed at treating Orlin Syndrome.
See More
Medicus Pharma Presents Phase 1 Data on Teverelix at AACE 2026
- Clinical Data Presentation: Medicus Pharma will present Phase 1 clinical data on Teverelix at the 2026 American Association of Clinical Endocrinology Annual Meeting, aiming to provide new therapies for hormone-driven diseases, particularly in women's health applications.
- Key Findings: In two Phase I studies conducted in Germany with 48 healthy premenopausal women, Teverelix demonstrated effective estradiol suppression and pharmacokinetic characteristics supporting infrequent dosing strategies, while showing good tolerability.
- Strategic Development Plan: The company plans to collaborate with Omics Labs in the UAE to develop Teverelix for symptomatic endometriosis, utilizing a genomics-enabled clinical development strategy designed to optimize patient selection and therapeutic response.
- Market Opportunity: With no long-acting injectable GnRH antagonists currently approved for endometriosis, Teverelix is positioned to become the first long-acting injectable therapy in this area, addressing the urgent market need for new treatments.
See More
Medicus Pharma Submits New Drug Study Protocol to FDA
- Clinical Trial Advancement: Medicus Pharma has submitted an optimized Phase 2 study protocol for its lead candidate Teverelix, aimed at treating acute urinary retention (AURr), a condition often linked to benign prostatic hyperplasia (BPH) that severely impacts quality of life.
- Trial Design Details: The study will enroll 126 patients and is designed to generate an early pharmacodynamic signal within approximately 12 weeks, with an overall duration of 52 weeks, including a 28-week treatment period followed by a 24-week observation phase to assess long-term outcomes.
- Market Potential Assessment: Medicus Pharma estimates a market opportunity of $6 billion for Teverelix, highlighting its commercial potential, especially given that current management options primarily rely on invasive catheterization.
- Stock Price Dynamics: MDCX shares have traded between $0.37 and $8.94 over the past year, closing at $0.44, up 6.43% from the previous trading day, indicating a positive market response to the drug development progress.
See More
Medicus Pharma Submits Optimized Phase 2 Study Design for Teverelix
- Optimized Study Design: Medicus Pharma has submitted an optimized Phase 2 clinical study design for Teverelix aimed at preventing recurrent acute urinary retention in benign prostatic hyperplasia patients, targeting a market of approximately $2 billion, showcasing the company's potential to address unmet clinical needs.
- Expert Leadership: The study is led by Dr. Steven A. Kaplan, a globally recognized urology expert with over 1,000 scientific publications, ensuring the study's scientific rigor and authority, thereby enhancing investor confidence.
- Cost Efficiency Improvement: The new design is expected to reduce the study size to approximately 126 patients, and through clear pharmacodynamic endpoints and interim analysis, significantly lower overall development costs while improving development efficiency, supporting earlier strategic partnership opportunities.
- Early Signal Generation: The study aims to generate early pharmacodynamic signals within approximately 12 weeks, assisting the company in making timely decisions in clinical development, further advancing Teverelix's commercialization process and enhancing market competitiveness.
See More
Medicus Pharma Clarifies SKNJCT-003 Clinical Data Results
- Clinical Data Clarification: Medicus Pharma clarified its Phase 2 clinical study results for SKNJCT-003, highlighting that the 200µg dose cohort demonstrated a 73% clinical clearance rate by Day 57, indicating potential value for non-surgical skin cancer treatment options.
- Role of Device-Only Arm: The study included a device-only arm (P-MNA/C-MNA) that did not contain active drug, primarily serving to provide scientific context; while its mechanism is of academic interest, it does not impact the therapeutic positioning of SkinJect, which relies on intratumoral delivery of doxorubicin via microneedle arrays.
- Registration Strategy Focus: The company plans to concentrate its registrational development strategy on the 200µg dose, with future efforts aimed at optimizing study design and biological activity assessments to ensure alignment with regulatory guidance, thereby advancing the SkinJect program.
- Management Commentary: Dr. Raza Bokhari, Executive Chairman and CEO of Medicus, stated that the positive results from the 200µg cohort support the therapeutic value of SkinJect and lay a foundation for future registrational studies, showcasing the company's strategic potential in the non-invasive treatment space.
See More
Medicus Pharma Submits Orphan Drug Designation for SkinJect®
- Orphan Drug Application: Medicus Pharma has submitted an Orphan Drug Designation application to the U.S. FDA for SkinJect® (D-MNA) targeting basal cell carcinoma in patients with Gorlin Syndrome, marking a strategic expansion into a high unmet need orphan indication that is expected to enhance market competitiveness.
- High-Burden Rare Disease: Gorlin Syndrome affects approximately 11,000 patients in the U.S., with individuals potentially developing dozens to over 1,000 basal cell carcinomas throughout their lives; current treatments rely heavily on surgery, lacking FDA-approved therapies, making SkinJect® a promising solution to alleviate both physical and psychological burdens on patients.
- Localized Treatment Advantages: SkinJect® is a dissolvable microneedle array designed for direct delivery of doxorubicin into tumor tissue, featuring high local concentration and minimal systemic exposure, which is particularly beneficial for managing multiple lesions in Gorlin Syndrome patients, potentially improving their treatment experience significantly.
- Clinical Research Progress: SkinJect® has demonstrated a favorable safety profile and evidence of clinical clearance in Phase 1 and Phase 2 studies for basal cell carcinoma; if granted orphan drug status, it will provide Medicus with 7 years of market exclusivity, enhancing its differentiated clinical and regulatory pathway.
See More
Medicus Pharma Files Application for Orphan Drug Designation with U.S. FDA for Skinject® in Gorlin Syndrome
- Medicus Pharma Submission: Medicus Pharma has submitted an application to the U.S. FDA for the designation of a new orphan drug.
- Targeted Condition: The application is specifically for the drug "Skinject®" aimed at treating Orlin Syndrome.
See More
Medicus Pharma Presents Phase 1 Data on Teverelix at AACE 2026
- Clinical Data Presentation: Medicus Pharma will present Phase 1 clinical data on Teverelix at the 2026 American Association of Clinical Endocrinology Annual Meeting, aiming to provide new therapies for hormone-driven diseases, particularly in women's health applications.
- Key Findings: In two Phase I studies conducted in Germany with 48 healthy premenopausal women, Teverelix demonstrated effective estradiol suppression and pharmacokinetic characteristics supporting infrequent dosing strategies, while showing good tolerability.
- Strategic Development Plan: The company plans to collaborate with Omics Labs in the UAE to develop Teverelix for symptomatic endometriosis, utilizing a genomics-enabled clinical development strategy designed to optimize patient selection and therapeutic response.
- Market Opportunity: With no long-acting injectable GnRH antagonists currently approved for endometriosis, Teverelix is positioned to become the first long-acting injectable therapy in this area, addressing the urgent market need for new treatments.
See More
Medicus Pharma Submits New Drug Study Protocol to FDA
- Clinical Trial Advancement: Medicus Pharma has submitted an optimized Phase 2 study protocol for its lead candidate Teverelix, aimed at treating acute urinary retention (AURr), a condition often linked to benign prostatic hyperplasia (BPH) that severely impacts quality of life.
- Trial Design Details: The study will enroll 126 patients and is designed to generate an early pharmacodynamic signal within approximately 12 weeks, with an overall duration of 52 weeks, including a 28-week treatment period followed by a 24-week observation phase to assess long-term outcomes.
- Market Potential Assessment: Medicus Pharma estimates a market opportunity of $6 billion for Teverelix, highlighting its commercial potential, especially given that current management options primarily rely on invasive catheterization.
- Stock Price Dynamics: MDCX shares have traded between $0.37 and $8.94 over the past year, closing at $0.44, up 6.43% from the previous trading day, indicating a positive market response to the drug development progress.
See More
Medicus Pharma Submits Optimized Phase 2 Study Design for Teverelix
- Optimized Study Design: Medicus Pharma has submitted an optimized Phase 2 clinical study design for Teverelix aimed at preventing recurrent acute urinary retention in benign prostatic hyperplasia patients, targeting a market of approximately $2 billion, showcasing the company's potential to address unmet clinical needs.
- Expert Leadership: The study is led by Dr. Steven A. Kaplan, a globally recognized urology expert with over 1,000 scientific publications, ensuring the study's scientific rigor and authority, thereby enhancing investor confidence.
- Cost Efficiency Improvement: The new design is expected to reduce the study size to approximately 126 patients, and through clear pharmacodynamic endpoints and interim analysis, significantly lower overall development costs while improving development efficiency, supporting earlier strategic partnership opportunities.
- Early Signal Generation: The study aims to generate early pharmacodynamic signals within approximately 12 weeks, assisting the company in making timely decisions in clinical development, further advancing Teverelix's commercialization process and enhancing market competitiveness.
See More
Medicus Pharma Clarifies SKNJCT-003 Clinical Data Results
- Clinical Data Clarification: Medicus Pharma clarified its Phase 2 clinical study results for SKNJCT-003, highlighting that the 200µg dose cohort demonstrated a 73% clinical clearance rate by Day 57, indicating potential value for non-surgical skin cancer treatment options.
- Role of Device-Only Arm: The study included a device-only arm (P-MNA/C-MNA) that did not contain active drug, primarily serving to provide scientific context; while its mechanism is of academic interest, it does not impact the therapeutic positioning of SkinJect, which relies on intratumoral delivery of doxorubicin via microneedle arrays.
- Registration Strategy Focus: The company plans to concentrate its registrational development strategy on the 200µg dose, with future efforts aimed at optimizing study design and biological activity assessments to ensure alignment with regulatory guidance, thereby advancing the SkinJect program.
- Management Commentary: Dr. Raza Bokhari, Executive Chairman and CEO of Medicus, stated that the positive results from the 200µg cohort support the therapeutic value of SkinJect and lay a foundation for future registrational studies, showcasing the company's strategic potential in the non-invasive treatment space.
See More
